Hypotonic Hydrogel Formulations for Sustained Mucosal Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug delivery methods struggle to achieve sustained local drug concentrations and effective distribution at mucosal surfaces due to rapid degradation, shedding, and systemic absorption, particularly in areas like the vagina and eyes, necessitating improved compositions that act as barriers to pathogen entry and provide retention and sustained release.
Innovation Solution
Hypotonic gelling vehicles are used to solubilize drugs, enhancing mucosal penetration and distribution by administering hydrogel-forming polymers like Pluronic F127 and F98 below their critical gelling concentration, allowing the polymers to absorb into mucosal tissues and gel against the epithelium, forming a sustained-release barrier.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If traditional soluble dosage forms are used for drug delivery to mucosal surfaces, then the formulation is easy to administer, but the drug concentration is rapidly lost due to degradation, shedding, and systemic absorption
Solution Approach 1:
The patent utilizes the sol-gel phase transition of thermosensitive polymers (specifically Pluronic block copolymers) to transform the formulation from a liquid state during administration to a gel state at the mucosal surface. This phase transition enables easy administration as a liquid while providing sustained retention as a gel matrix that resists shedding and degradation, directly resolving the contradiction between ease of administration and retention time
Solution Approach 2:
The patent changes the physical-chemical parameters of the formulation by using hypotonic solutions that trigger water influx into the gel network, causing swelling and enhanced gelation at the mucosal surface. This parameter change (tonicity) allows the formulation to maintain liquid properties for easy administration while transforming into a retained gel structure at the target site, addressing both ease of administration and retention requirements
2Duration of action of moving object
If hydrogel-forming polymers are administered at or above critical gelling concentration, then sustained release is achieved, but distribution into mucosal folds is limited
Solution Approach 1:
The patent applies preliminary action by administering the polymer at concentrations below the critical gelling concentration, allowing the formulation to first distribute widely into mucosal folds as a liquid. Subsequently, in vivo gelation occurs after distribution is complete, ensuring both broad area coverage and sustained release capability without the limitations of pre-gelled formulations
3Stability of the object's composition
If isosmotic or hypertonic formulations are used, then stability is maintained, but mucosal penetration and distribution are reduced
Solution Approach 1:
The patent changes the tonicity parameter from isosmotic or hypertonic to hypotonic, which triggers osmotic water influx into the gel network. This parameter change enhances mucosal penetration by creating an osmotic gradient that drives the formulation deeper into tissues while the resulting gel structure maintains compositional stability, resolving the contradiction between penetration speed and stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hypotonic gelling vehicles enhance drug delivery by increasing retention and penetration, providing up to 10-fold concentration of active agents at mucosal surfaces and effectively trapping pathogens, while maintaining safety and comfort.
Implementation Method 1
The hypotonic formulations defined herein contain a gel forming polymer that is (i) between greater than 12 and less than 24% Pluronic ®
Implementation Method 2
hypotonic gelling vehicles are used to solubilize drugs, enhancing mucosal penetration and distribution by administering hydrogel-forming polymers like Pluronic F127 and F98 below their critical gelling concentration, allowing the polymers to absorb into mucosal tissues and gel against the epithelium
Data Source
Figure 1~2
Figure 3
Figure 4
AI summary
Hypotonic gelling vehicles are used as solubilizing agents for drugs and as a means to provide sustained drug delivery to a mucosal tissue. Solubilizing drugs at higher concentrations enhances drug penetration into the tissues of the body, while the hypotonic gelling vehicle further improves distribution of the drug over a larger surface area for increased absorption and sustained release for reduced side effects and longer duration of action.